In-silico lead identification of the pan-mutant IDH1 and IDH2 inhibitors to target glioblastoma

Vignesh Balaji E, Sairaj Satarker, B. Harish Kumar, Samyak Pandey, Sumit Raosaheb Birangal, Usha Y. Nayak, K. Sreedhara Ranganath Pai

Research output: Contribution to journalArticlepeer-review


Glioblastoma (GBM) is an aggressive malignant type of brain tumor. Targeting one single intracellular pathway might not alleviate the disease, rather it activates the other molecular pathways that lead to the worsening of the disease condition. Therefore, in this study, we attempted to target both isocitrate dehydrogenase 1 (IDH1) and IDH2, which are one of the most commonly mutated proteins in GBM and other cancer types. Here, standard precision and extra precision docking, IFD, MM-GBSA, QikProp, and molecular dynamics (MD) simulation were performed to identify the potential dual inhibitor for IDH1 and IDH2 from the enamine database containing 59,161 ligands. Upon docking the ligands with IDH1 (PDB: 6VEI) and IDH2 (PDB: 6VFZ), the top eight ligands were selected, based on the XP Glide score. These ligands produced favourable MMGBSA scores and ADME characteristics. Finally, the top four ligands 12953, 44825, 51295, and 53210 were subjected to MD analysis. Interestingly, 53210 showed maximum interaction with Gln 277 for 99% in IDH1 and Gln 316 for 100% in IDH2, which are the crucial amino acids for the inhibitory function of IDH1 and IDH2 to target GBM. Therefore, the present study attempts to identify the novel molecules which could possess a pan-inhibitory action on both IDH1 and IDH that could be crucial in the management of GBM. Yet further evaluation involving in vitro and in vivo studies is warranted to support the data in our current study. Communicated by Ramaswamy H. Sarma.

Original languageEnglish
JournalJournal of Biomolecular Structure and Dynamics
Publication statusAccepted/In press - 2023

All Science Journal Classification (ASJC) codes

  • Structural Biology
  • Molecular Biology


Dive into the research topics of 'In-silico lead identification of the pan-mutant IDH1 and IDH2 inhibitors to target glioblastoma'. Together they form a unique fingerprint.

Cite this